Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Due to the substantial increase in overseas sales of the COVID-19 Test kit launched in 2021, many listed IVD companies estimate that their profits will surge in 2021.

Scientists have just slotted into place a big piece of the puzzle that explains how our blood cells mount their first line of defence against viruses. They hope this discovery will help them one day better control the response to either boost it or calm it down as appropriate.

Multiple diagnostic firms released preliminary earnings results for the fourth quarter and full year of 2021 on Monday, including CareDx, Castle Biosciences, Lucira Health, OpGen, Adaptive Biotechnologies, and Sema4.

Merck, a leading science and technology company, has signed a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million in cash.

Quidel is set to beat analyst expectations in the fourth quarter on the back of rising demand for COVID-19 tests that brought revenues up to around $635 million.

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 25, 2021.

To make fusion energy a viable resource for the world’s energy grid, researchers need to understand the turbulent motion of plasmas: a mix of ions and electrons swirling around in reactor vessels.

Ortho Clinical Diagnostics announced preliminary financial results for the fourth quarter after the close of the market on Thursday, saying it expects total revenues of between $520 million and $522 million, up approximately 1 percent year over year from $517 million.

Thermo Fisher Scientific, the world leader in serving science, and PeproTech, a leading developer and manufacturer of recombinant proteins, today announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2021 for a total cash purchase price of approximately $1.85 billion.

On January 7, Hotgen Biotech released a performance forecast. The company expects the net profit attributable to the shareholders of the listed company from January to December 2021 to be CNY 2 billion to CNY 2.35 billion, with a year-on-year change of 1684.65% to 1996.97%.